

Maureen P M H Rutten-Van Mäjlken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1775959/publications.pdf>

Version: 2024-02-01

236
papers

12,563
citations

47006

47
h-index

29157

104
g-index

245
all docs

245
docs citations

245
times ranked

11806
citing authors

#	ARTICLE	IF	CITATIONS
1	An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2013, 188, e13-e64.	5.6	2,668
2	Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal, 2008, 31, 416-469.	6.7	732
3	Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis) Tj ETQq1 1 0.784314 rgBT /Overlock 1 2005, 365, 1552-1560.	13.7	621
4	Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. New England Journal of Medicine, 2011, 364, 1093-1103.	27.0	603
5	The cost diary. Journal of Clinical Epidemiology, 2000, 53, 688-695.	5.0	293
6	Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. Journal of Allergy and Clinical Immunology, 2013, 132, 353-360.e2.	2.9	263
7	Nutritional assessment and therapy in COPD: a European Respiratory Society statement. European Respiratory Journal, 2014, 44, 1504-1520.	6.7	233
8	The Impact of Aging and Smoking on the Future Burden of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 590-596.	5.6	190
9	Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Annals of the Rheumatic Diseases, 2002, 61, 429-437.	0.9	182
10	Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?. Chest, 2006, 130, 1117-1128.	0.8	177
11	Clinical and economic impact of non-adherence in COPD: A systematic review. Respiratory Medicine, 2014, 108, 103-113.	2.9	176
12	Integrated disease management interventions for patients with chronic obstructive pulmonary disease. The Cochrane Library, 2013, , CD009437.	2.8	168
13	Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax, 2010, 65, 7-13.	5.6	159
14	Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. European Respiratory Journal, 2011, 37, 508-515.	6.7	152
15	The SELFIE framework for integrated care for multi-morbidity: Development and description. Health Policy, 2018, 122, 12-22.	3.0	149
16	Influenza Vaccination in Children with Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 488-493.	5.6	131
17	Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial. Arthritis and Rheumatism, 2002, 47, 459-467.	6.7	130
18	Resource use and risk factors in high-cost exacerbations of COPD. Respiratory Medicine, 2004, 98, 883-891.	2.9	128

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions: A Dynamic Modeling Study. <i>Value in Health</i> , 2005, 8, 178-190.	0.3	126
20	One-year cost-effectiveness of tiotropiumversusipratropium to treat chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2004, 23, 241-249.	6.7	118
21	Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. <i>BMJ, The</i> , 2014, 349, g5392-g5392.	6.0	118
22	Chronic low-back pain: What does cognitive coping skills training add to operant behavioral treatment? Results of a randomized clinical trial.. <i>Journal of Consulting and Clinical Psychology</i> , 1999, 67, 931-944.	2.0	114
23	Efficacy and Costs of Nutritional Rehabilitation in Muscle-Wasted Patients With Chronic Obstructive Pulmonary Disease in a Community-Based Setting: A Prespecified Subgroup Analysis of the INTERCOM Trial. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 179-187.	2.5	113
24	Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. <i>Thorax</i> , 2010, 65, 711-718.	5.6	111
25	Relevant models and elements of integrated care for multi-morbidity: Results of a scoping review. <i>Health Policy</i> , 2018, 122, 23-35.	3.0	103
26	A dynamic population model of disease progression in COPD. <i>European Respiratory Journal</i> , 2005, 26, 223-233.	6.7	102
27	Statistical analysis of cost outcomes in a randomized controlled clinical trial. <i>Health Economics (United Kingdom)</i> , 1994, 3, 333-345.	1.7	101
28	Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 732-740.	0.9	100
29	COVID-19 Contact Tracing Apps: Predicted Uptake in the Netherlands Based on a Discrete Choice Experiment. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20741.	3.7	99
30	Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries. <i>Value in Health</i> , 2005, 8, 32-46.	0.3	95
31	Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. , 1998, 7, 39-51.		80
32	Association between lung function and exacerbation frequency in patients with COPD. <i>International Journal of COPD</i> , 2010, 5, 435.	2.3	79
33	Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. <i>European Journal of Health Economics</i> , 2007, 8, 123-135.	2.8	77
34	Is INTERdisciplinary COMMunity-based COPD management (INTERCOM) cost-effective?. <i>European Respiratory Journal</i> , 2010, 35, 79-87.	6.7	72
35	Exploring payment schemes used to promote integrated chronic care in Europe. <i>Health Policy</i> , 2013, 113, 296-304.	3.0	68
36	Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. <i>Current Medical Research and Opinion</i> , 2008, 24, 51-61.	1.9	67

#	ARTICLE	IF	CITATIONS
37	Costs and effects of new professional roles: Evidence from a literature review. <i>Health Policy</i> , 2015, 119, 1176-1187.	3.0	65
38	Two-Year Bronchodilator Treatment in Patients with Mild Airflow Obstruction. <i>Chest</i> , 1992, 102, 1384-1391.	0.8	63
39	Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. <i>Respiratory Medicine</i> , 2006, 100, 83-86.	2.9	63
40	Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysis. <i>Respiratory Research</i> , 2014, 15, 66.	3.6	63
41	Costs of ankylosing spondylitis in three European countries: the patient's perspective. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 741-747.	0.9	60
42	Surgery is more cost-effective than splinting for carpal tunnel syndrome in the Netherlands: results of an economic evaluation alongside a randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2006, 7, 86.	1.9	55
43	Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial Setting. <i>Pharmacoeconomics</i> , 2003, 21, 1103-1112.	3.3	54
44	e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial. <i>European Respiratory Journal</i> , 2016, 48, 758-767.	6.7	54
45	Cost Effectiveness of Interventions for Lateral Epicondylitis. <i>Pharmacoeconomics</i> , 2004, 22, 185-195.	3.3	52
46	Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. <i>Value in Health</i> , 2008, 11, 1070-1080.	0.3	52
47	Digital Health Transformation of Integrated Care in Europe: Overarching Analysis of 17 Integrated Care Programs. <i>Journal of Medical Internet Research</i> , 2019, 21, e14956.	4.3	52
48	Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. <i>BMC Pulmonary Medicine</i> , 2014, 14, 163.	2.0	51
49	Towards incentivising integration: A typology of payments for integrated care. <i>Health Policy</i> , 2018, 122, 963-969.	3.0	51
50	Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD Measurements. <i>Calcified Tissue International</i> , 2016, 98, 235-243.	3.1	49
51	Projecting the COPD population and costs in England and Scotland: 2011 to 2030. <i>Scientific Reports</i> , 2016, 6, 31893.	3.3	48
52	The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. <i>European Respiratory Journal</i> , 2001, 17, 329-336.	6.7	47
53	The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis. <i>BMC Pulmonary Medicine</i> , 2013, 13, 40.	2.0	47
54	Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. <i>Health Policy</i> , 2011, 101, 122-132.	3.0	46

#	ARTICLE	IF	CITATIONS
55	The Cost Effectiveness of Early Treatment with Fluticasone Propionate 250 µg Twice a Day in Subjects with Obstructive Airway Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 2057-2066.	5.6	45
56	Resource Use and Costs of Patients With Glaucoma or Ocular Hypertension: A One-year Study Based on Retrospective Chart Review in the Netherlands. <i>Journal of Glaucoma</i> , 2001, 10, 184-191.	1.6	44
57	Influenza vaccination in asthmatic children: effects on quality of life and symptoms. <i>European Respiratory Journal</i> , 2004, 24, 925-931.	6.7	44
58	Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA). <i>BMC Health Services Research</i> , 2018, 18, 576.	2.2	43
59	Performing Economic Evaluation of Integrated Care: Highway to Hell or Stairway to Heaven?. <i>International Journal of Integrated Care</i> , 2016, 16, 3.	0.2	43
60	Treatment with inhaled corticosteroids in asthma is too often discontinued. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 411-422.	1.9	42
61	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. <i>Value in Health</i> , 2014, 17, 525-536.	0.3	41
62	Cost Consequences of Implementing an Electronic Decision Support System for Ordering Laboratory Tests in Primary Care: Evidence from a Controlled Prospective Study in The Netherlands. <i>Clinical Chemistry</i> , 2007, 53, 213-219.	3.2	40
63	Should I Stay or Should I Go Home? A Latent Class Analysis of a Discrete Choice Experiment on Hospital-At-Home. <i>Value in Health</i> , 2014, 17, 588-596.	0.3	39
64	Evaluation of a large scale implementation of disease management programmes in various Dutch regions: a study protocol. <i>BMC Health Services Research</i> , 2011, 11, 6.	2.2	37
65	Patient preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: Results of a randomised controlled trial. <i>International Journal of Nursing Studies</i> , 2013, 50, 1537-1549.	5.6	36
66	Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. <i>Pharmacoeconomics</i> , 2017, 35, 43-63.	3.3	36
67	Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care. <i>BMJ Open</i> , 2016, 6, e011519.	1.9	35
68	Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2012, 30, 271-302.	3.3	34
69	Cochrane corner: is integrated disease management for patients with COPD effective?: Table 1. <i>Thorax</i> , 2014, 69, 1053-1055.	5.6	34
70	Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma. <i>Pharmacoeconomics</i> , 1998, 14, 671-684.	3.3	33
71	Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health. <i>Pharmacoeconomics</i> , 2009, 27, 465-477.	3.3	33
72	TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. <i>Pharmacoeconomics</i> , 2019, 37, 1391-1408.	3.3	33

#	ARTICLE	IF	CITATIONS
73	e-Monitoring of Asthma Therapy to Improve Compliance in children using a real-time medication monitoring system (RTMM): the e-MATIC study protocol. BMC Medical Informatics and Decision Making, 2013, 13, 38.	3.0	32
74	Cost-effectiveness of integrated COPD care: the RECODE cluster randomised trial. BMJ Open, 2015, 5, e007284.	1.9	32
75	THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS. International Journal of Technology Assessment in Health Care, 2016, 32, 46-53.	0.5	32
76	Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health, 2017, 20, 1260-1269.	0.3	32
77	Economic Modeling in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 630-634.	3.5	31
78	Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2016, 50, 605-616.	1.4	31
79	Evaluation of integrated care services in Catalonia: population-based and service-based real-life deployment protocols. BMC Health Services Research, 2019, 19, 370.	2.2	31
80	A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease. Pharmacoeconomics, 2007, 25, 695-711.	3.3	30
81	Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. Value in Health, 2011, 14, 1039-1047.	0.3	30
82	RECODE: Design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care. BMC Pulmonary Medicine, 2013, 13, 17.	2.0	30
83	Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. International Journal of COPD, 2017, Volume 12, 3183-3194.	2.3	30
84	Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial. International Journal of COPD, 2008, Volume 3, 443-451.	2.3	29
85	Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants. Cost Effectiveness and Resource Allocation, 2014, 12, 17.	1.5	29
86	Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. Medical Decision Making, 2017, 37, 469-480.	2.4	29
87	Principles of economic evaluation for interventions of chronic musculoskeletal pain. European Journal of Pain, 1999, 3, 343-353.	2.8	28
88	Does influenza vaccination exacerbate asthma in children?. Vaccine, 2004, 23, 91-96.	3.8	28
89	Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A cross-sectional study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2014, 23, 30-37.	2.3	28
90	Comparison of cardiovascular risk algorithms in patients with <i>vs</i> without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. Rheumatology, 2017, 56, 777-786.	1.9	28

#	ARTICLE	IF	CITATIONS
91	Development of the Assessment of Burden of COPD tool: an integrated tool to measure the burden of COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14021.	2.6	27
92	Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. <i>Arthritis Care and Research</i> , 2016, 68, 308-317.	3.4	27
93	Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: The randomized controlled NUTRAIN trial. <i>Clinical Nutrition</i> , 2020, 39, 405-413.	5.0	27
94	Drivers of successful implementation of integrated care for multi-morbidity: Mechanisms identified in 17 case studies from 8 European countries. <i>Social Science and Medicine</i> , 2021, 277, 113728.	3.8	27
95	Crossing Borders: Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European Countries. <i>Value in Health</i> , 2010, 13, 230-241.	0.3	26
96	Utility Estimation in Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2011, 29, 917-932.	3.3	26
97	Early assisted discharge with generic community nursing for chronic obstructive pulmonary disease exacerbations: results of a randomised controlled trial. <i>BMJ Open</i> , 2012, 2, e001684.	1.9	26
98	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 75.	2.7	26
99	Effectiveness and cost-effectiveness of early assisted discharge for Chronic Obstructive Pulmonary Disease exacerbations: the design of a randomised controlled trial. <i>BMC Public Health</i> , 2010, 10, 618.	2.9	25
100	Cost-Effectiveness of Early Assisted Discharge for COPD Exacerbations in The Netherlands. <i>Value in Health</i> , 2013, 16, 517-528.	0.3	24
101	BROADER ECONOMIC EVALUATION OF DISEASE MANAGEMENT PROGRAMS USING MULTI-CRITERIA DECISION ANALYSIS. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 301-308.	0.5	24
102	Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. <i>Medical Decision Making</i> , 2017, 37, 453-468.	2.4	24
103	Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. <i>Pharmacoeconomics</i> , 2021, 39, 771-788.	3.3	24
104	The role of disease management programs in the health behavior of chronically ill patients. <i>Patient Education and Counseling</i> , 2014, 95, 137-142.	2.2	23
105	External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. <i>Value in Health</i> , 2017, 20, 397-403.	0.3	23
106	Cost comparison of two implantable cardiac monitors in two different settings: Reveal XT in a catheterization laboratory vs. Reveal LINQ in a procedure room. <i>Europace</i> , 2016, 18, 919-924.	1.7	22
107	What Is the Potential of Tissue-Engineered Pulmonary Valves in Children?. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1845-1853.	1.3	22
108	Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2010, 19, 68-74.	2.3	21

#	ARTICLE	IF	CITATIONS
109	Exploring the variation in implementation of a COPD disease management programme and its impact on health outcomes: a post hoc analysis of the RECODE cluster randomised trial. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15071.	2.6	21
110	Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. <i>Rheumatology</i> , 2016, 55, 809-816.	1.9	21
111	Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , 2017, 37, 440-452.	2.4	21
112	Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries. <i>BMJ Open</i> , 2018, 8, e021072.	1.9	21
113	Is the EQ-5D responsive to recovery from a moderate COPD exacerbation?. <i>Respiratory Medicine</i> , 2011, 105, 1195-1202.	2.9	20
114	Cost-Effectiveness of Disease Management Programs for Cardiovascular Risk and COPD in The Netherlands. <i>Value in Health</i> , 2015, 18, 977-986.	0.3	20
115	Conceptual model for early health technology assessment of current and novel heart valve interventions. <i>Open Heart</i> , 2016, 3, e000500.	2.3	20
116	Self-report versus care provider registration of healthcare utilization: Impact on cost and cost-utility. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 588-595.	0.5	19
117	Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. <i>PLoS ONE</i> , 2015, 10, e0138225.	2.5	19
118	The Assessment of Burden of COPD (ABC) Scale: A Reliable and Valid Questionnaire. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 431-438.	1.6	19
119	How much does a heart valve implantation cost and what are the health care costs afterwards?. <i>Open Heart</i> , 2018, 5, e000672.	2.3	19
120	The patient at the centre: evidence from 17 European integrated care programmes for persons with complex needs. <i>BMC Health Services Research</i> , 2020, 20, 1102.	2.2	19
121	Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 501-524.	2.1	19
122	Informal caregiver strain, preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: Results of a randomised controlled trial. <i>International Journal of Nursing Studies</i> , 2014, 51, 1093-1102.	5.6	18
123	Development of an integral assessment approach of health status in patients with obstructive airway diseases: the CORONA study. <i>International Journal of COPD</i> , 2015, 10, 2413.	2.3	18
124	Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence. <i>Respiratory Medicine</i> , 2016, 110, 34-45.	2.9	18
125	Common challenges faced in EU-funded projects on integrated care for vulnerable persons. <i>International Journal of Integrated Care</i> , 2017, 17, 17.	0.2	18
126	Application of a theoretical model to evaluate COPD disease management. <i>BMC Health Services Research</i> , 2010, 10, 81.	2.2	17

#	ARTICLE	IF	CITATIONS
127	Bioprosthetic aortic valve replacement in elderly patients: Meta-analysis and microsimulation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 2189-2197.e14.	0.8	17
128	Integrated Care for Frail Elderly: A Qualitative Study of a Promising Approach in The Netherlands. <i>International Journal of Integrated Care</i> , 2019, 19, 16.	0.2	17
129	If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. <i>Addiction</i> , 2010, 105, 1088-1097.	3.3	16
130	Mapping the Clinical Chronic Obstructive Pulmonary Disease Questionnaire onto Generic Preference-Based EQ-5D Values. <i>Value in Health</i> , 2015, 18, 299-307.	0.3	16
131	Impact of financial agreements in European chronic care on health care expenditure growth. <i>Health Policy</i> , 2016, 120, 420-430.	3.0	16
132	The management of cardiovascular disease in the Netherlands: analysis of different programmes. <i>International Journal of Integrated Care</i> , 2013, 13, e028.	0.2	16
133	Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat [®] fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 391-401.	2.6	15
134	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 179.	2.7	15
135	The potential for integrated care programmes to improve quality of care as assessed by patients with COPD: early results from a real-world implementation study in The Netherlands. <i>International Journal of Integrated Care</i> , 2012, 12, e191.	0.2	15
136	Comparison of EQ-5D and SF-6D utilities in Pompe disease. <i>Quality of Life Research</i> , 2015, 24, 837-844.	3.1	14
137	Exploring the Impact of Adding a Respiratory Dimension to the EQ-5D-5L. <i>Medical Decision Making</i> , 2019, 39, 393-404.	2.4	14
138	Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine. <i>Value in Health</i> , 2019, 22, 313-321.	0.3	14
139	Bottom-up implementation of disease-management programmes: results of a multisite comparison. <i>BMJ Quality and Safety</i> , 2011, 20, 76-86.	3.7	13
140	Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool: study protocol of a cluster randomised trial in primary and secondary care. <i>BMC Pulmonary Medicine</i> , 2014, 14, 131.	2.0	13
141	Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 557-559.	1.4	13
142	A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 135.	3.5	13
143	Comparing patients' and other stakeholders' preferences for outcomes of integrated care for multimorbidity: a discrete choice experiment in eight European countries. <i>BMJ Open</i> , 2020, 10, e037547.	1.9	13
144	Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients. <i>European Journal of Health Economics</i> , 2020, 21, 557-572.	2.8	13

#	ARTICLE	IF	CITATIONS
145	Care delivery pathways for Chronic Obstructive Pulmonary Disease in England and the Netherlands: a comparative study. <i>International Journal of Integrated Care</i> , 2012, 12, e40.	0.2	13
146	The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis. <i>Value in Health</i> , 2022, 25, 1428-1438.	0.3	13
147	Cost effectiveness of guideline advice for children with asthma: A literature review. <i>Pediatric Pulmonology</i> , 2002, 34, 442-454.	2.0	12
148	Identifying and explaining the variability in development and implementation costs of disease management programs in the Netherlands. <i>BMC Health Services Research</i> , 2014, 14, 518.	2.2	12
149	Systematic review of model-based economic evaluations of heart valve implantations. <i>European Journal of Health Economics</i> , 2018, 19, 241-255.	2.8	12
150	How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , 2020, 40, 619-632.	2.4	12
151	The risk of overestimating cost savings from hospital-at-home schemes: A literature review. <i>International Journal of Nursing Studies</i> , 2020, 109, 103652.	5.6	12
152	The impact of the involvement of a healthcare professional on the usage of an eHealth platform: a retrospective observational COPD study. <i>Respiratory Research</i> , 2021, 22, 88.	3.6	12
153	The disease burden of multimorbidity and its interaction with educational level. <i>PLoS ONE</i> , 2020, 15, e0243275.	2.5	12
154	The Economic Effects of Screening for Obstructive Airway Disease: An Economic Analysis of the DIMCA Program. <i>Preventive Medicine</i> , 2000, 30, 302-308.	3.4	11
155	Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. <i>European Journal of Health Economics</i> , 2011, 12, 397-404.	2.8	11
156	Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , 2016, 19, 800-810.	0.3	11
157	ABC Index: quantifying experienced burden of COPD in a discrete choice experiment and predicting costs. <i>BMJ Open</i> , 2017, 7, e017831.	1.9	11
158	Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. <i>Value in Health</i> , 2018, 21, 193-202.	0.3	11
159	Implementation of palliative care consult Service in Hungary – integration barriers and facilitators. <i>BMC Palliative Care</i> , 2020, 19, 41.	1.8	11
160	A Short Term Cost-Effectiveness Model For Oral Antidiabetic Medicines in Europe. <i>Pharmacoeconomics</i> , 1998, 13, 317-326.	3.3	10
161	A conceptual disease model for adult Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 112.	2.7	10
162	Cost-Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 927-935.	3.4	10

#	ARTICLE	IF	CITATIONS
163	Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. BMC Health Services Research, 2019, 19, 131.	2.2	10
164	Bundled payments for chronic diseases increased health care expenditure in the Netherlands, especially for multimorbid patients.. Health Policy, 2021, 125, 751-759.	3.0	10
165	An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. Advances in Therapy, 2009, 26, 872-885.	2.9	9
166	Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. European Respiratory Journal, 2013, 41, 556-564.	6.7	9
167	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS ONE, 2018, 13, e0205013.	2.5	9
168	Raising the awareness: projecting the future burden of COPD with the BOLD model. European Respiratory Journal, 2009, 34, 787-789.	6.7	8
169	Comparing Methods of Data Synthesis. Pharmacoeconomics, 2011, 29, 239-250.	3.3	8
170	“To use or not to use”: a qualitative study to evaluate experiences of healthcare providers and patients with the assessment of burden of COPD (ABC) tool. Npj Primary Care Respiratory Medicine, 2016, 26, 16074.	2.6	8
171	The Role of Value-of-Information Analysis in a Health Care Research Priority Setting. Medical Decision Making, 2013, 33, 472-489.	2.4	7
172	The Road Not Taken: Transferability Issues in Multinational Trials. Pharmacoeconomics, 2013, 31, 863-876.	3.3	7
173	Not Simply More of the Same. Medical Decision Making, 2014, 34, 1048-1058.	2.4	7
174	Adjusting for COPD severity in database research: developing and validating an algorithm. International Journal of COPD, 2011, 6, 669.	2.3	6
175	Combination of Inhaled Corticosteroids and Î2-Agonists in Asthma. BioDrugs, 1996, 6, 489-505.	0.7	5
176	A Choice That Matters?. Pharmacoeconomics, 2013, 31, 719-730.	3.3	5
177	Exploring the variability of patient costs in disease management programs: a hierarchical modelling approach. Applied Economics, 2014, 46, 940-951.	2.2	5
178	Comprehensive Diagnostic Assessment of Health Status of Patients with Asthma or COPD: A Delphi Panel Study among Dutch Experts. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 190-199.	1.6	5
179	PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. International Journal of Technology Assessment in Health Care, 2017, 33, 609-619.	0.5	5
180	Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. International Journal of COPD, 2019, Volume 14, 447-456.	2.3	5

#	ARTICLE	IF	CITATIONS
181	Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. <i>Current Medical Research and Opinion</i> , 2008, 24, 51-61.	1.9	5
182	Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. <i>Croatian Medical Journal</i> , 2020, 61, 252-259.	0.7	5
183	Value-based person-centred integrated care for frail elderly living at home: a quasi-experimental evaluation using multicriteria decision analysis. <i>BMJ Open</i> , 2022, 12, e054672.	1.9	5
184	Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis. <i>Value in Health</i> , 2015, 18, 100-109.	0.3	4
185	The Fold-in, Fold-out Design for DCE Choice Tasks: Application to Burden of Disease. <i>Medical Decision Making</i> , 2019, 39, 450-460.	2.4	4
186	Evaluating Complex Health and Social Care Program Using Multi-Criteria Decision Analysis: A Case Study of "Better Together in Amsterdam North". <i>Value in Health</i> , 2021, 24, 966-975.	0.3	4
187	Evaluating an integrated care pathway for frail elderly patients in Norway using multi-criteria decision analysis. <i>BMC Health Services Research</i> , 2021, 21, 884.	2.2	4
188	Evaluation of health care providers' role transition and satisfaction in hospital-at-home for chronic obstructive pulmonary disease exacerbations: a survey study. <i>BMC Health Services Research</i> , 2013, 13, 363.	2.2	3
189	Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study. <i>Value in Health</i> , 2021, 24, 1667-1675.	0.3	3
190	Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β_2 -agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. <i>BMJ Open</i> , 2021, 11, e049675.	1.9	3
191	Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure. <i>Value in Health</i> , 2021, 24, 1435-1445.	0.3	3
192	Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. <i>Health Economics (United Kingdom)</i> , 1998, 7, 39-51.	1.7	3
193	Evaluating Complex Interventions. , 2017, , 297-313.		3
194	Moving Beyond Quality-Adjusted Life-Years in Elderly Care: How Can Multicriteria Decision Analysis Complement Cost-Effectiveness Analysis in Local-Level Decision Making. <i>Value in Health</i> , 2022, 25, 1717-1725.	0.3	3
195	Early palliative care associated with lower costs for adults with advanced cancer: evidence from Hungary. <i>European Journal of Cancer Care</i> , 2021, 30, e13473.	1.5	2
196	PRS3 COST-EFFECTIVENESS OF ROFLUMILAST IN THE UK:A 1-YEAR STUDY IN PATIENTS WITH SEVERE TO VERY SEVERE COPD. <i>Value in Health</i> , 2006, 9, A260-A261.	0.3	1
197	Beyond the clinical impact of aortic and pulmonary valve implantation: health-related quality of life, informal care and productivity. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 751-759.	1.4	1
198	Exploring characteristics of COPD patients with clinical improvement after integrated disease management or usual care: post-hoc analysis of the RECODE study. <i>BMC Pulmonary Medicine</i> , 2020, 20, 176.	2.0	1

#	ARTICLE	IF	CITATIONS
199	E-monitoring of asthma therapy to improve compliance in children (E-MATIC). , 2015, , .		1
200	Heterogeneity in preferences for outcomes of integrated care for persons with multiple chronic diseases: a latent class analysis of a discrete choice experiment. Quality of Life Research, 2022, 31, 2775-2789.	3.1	1
201	Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis. JMIR Cardio, 2022, 6, e31302.	1.7	1
202	Costs and Effects of Inhaled Corticosteroids and Bronchodilators in Asthma and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 975-982.	5.6	0
203	A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe. Pharmacoeconomics, 1998, 14, 709-714.	3.3	0
204	MC3 PROJECTIONS FOR COPD IN THE NETHERLANDS: HOW THE TYPE OF PROJECTION AFFECTS THE ESTIMATED GROWTH IN PREVALENCE. Value in Health, 2002, 5, 455.	0.3	0
205	MC3 METAMODELLING FORTHE CALCULATION OF THE EXPECTED VALUE OF PERFECT INFORMATION ON INDIVIDUAL MODEL PARAMETERS. Value in Health, 2005, 8, A1-A2.	0.3	0
206	PRS10 PROJECTING THE FUTURE COSTS OF ASTHMA AND COPD IN THE NETHERLANDS. Value in Health, 2005, 8, A214.	0.3	0
207	PRS18 DOES QUALITY OF LIFE OF COPD PATIENTS AS MEASURED BY THE GENERIC EQ-5D DIFFERENTIATE BETWEEN COPD SEVERITY STAGES?. Value in Health, 2005, 8, A216-A217.	0.3	0
208	PRS12 EXPECTED VALUE OF PERFECT INFORMATION: A PRACTICAL EXAMPLE OF REDUCING DECISION UNCERTAINTY BY CONDUCTING ADDITIONAL RESEARCH. Value in Health, 2006, 9, A263-A264.	0.3	0
209	PRS18 MEASURING DISEASE-SPECIFIC UTILITIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTH- AND EXACERBATION PROFILES. Value in Health, 2006, 9, A265-A266.	0.3	0
210	MO3 COMPARING METHODS OF DATA SYNTHESIS: UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL. Value in Health, 2008, 11, A346.	0.3	0
211	PRS42 SMOKING-CESSATION ACROSS BORDERS: TRANSFERABILITY OF COST-EFFECTIVENESS RESULTS. Value in Health, 2008, 11, A459.	0.3	0
212	PMC7 SELF-REPORT VERSUS CAREGIVER REPORT OF HEALTH CARE UTILIZATION: IMPACT ON COST AND COST-EFFECTIVENESS. Value in Health, 2008, 11, A561.	0.3	0
213	PMC4 LARGELY IGNORED: THE IMPACT OF THE THRESHOLD VALUE FOR A QALY ON THE IMPORTANCE OF A TRANSFERABILITY FACTOR. Value in Health, 2009, 12, A387.	0.3	0
214	Tiotropium Reduces Exacerbations Versus Salmeterol Irrespective Of Baseline ICS Treatment In The Poet-COPD; Study. , 2011, , .		0
215	Seasonal Distribution Of Exacerbations In The Poet-COPD; Study. , 2011, , .		0
216	Assessment of Burden of COPD tool: evidence not perception. European Respiratory Journal, 2017, 50, 1700756.	6.7	0

#	ARTICLE	IF	CITATIONS
217	Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes. PLoS ONE, 2017, 12, e0171292.	2.5	0
218	Economic Evaluation of Integrated Care. , 2021, , 575-593.		0
219	Evaluating Complex Interventions. , 2021, , 611-627.		0
220	Evidence-based policy making: how cost-effective are disease management programs in the Netherlands?. International Journal of Integrated Care, 2014, 14, .	0.2	0
221	Assessing implementation variations of a disease management program in daily practice: the RECODE case study. International Journal of Integrated Care, 2014, 14, .	0.2	0
222	Does registration of performance indicators improve health outcomes in COPD?. , 2015, , .		0
223	External validation of exacerbation and mortality outcomes of health economic decision models for COPD. , 2016, , .		0
224	The assessment of burden of COPD (ABC) tool: What counts most?. , 2016, , .		0
225	Information exchange between primary care (PC) and secondary care (SC): What is considered important in COPD?. , 2016, , .		0
226	COPD medication adherence and quality of life. , 2016, , .		0
227	Exploring the impact of adding a respiratory dimension to the current EQ-5D descriptive system. , 2016, , .		0
228	What should be part of a comprehensive assessment of COPD?. , 2016, , .		0
229	The assessment of burden of COPD tool improves health related quality of life. , 2016, , .		0
230	Prediction models for exacerbations in different COPD patient populations: Results of five large databases. , 2016, , .		0
231	SELFIE, a novel Horizon2020 project on integrated care for multi-morbidity. International Journal of Integrated Care, 2016, 16, 304.	0.2	0
232	Kicking off the Special Interest Group Health Economics in Integrated Care â€“ key questions and actions to move research forward. International Journal of Integrated Care, 2016, 16, 269.	0.2	0
233	Economic Evaluation of Integrated Care. , 2017, , 315-332.		0
234	Modeling the cost-effectiveness of stratified medicine in COPD. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
235	Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results. , 2018, , .		0
236	Clinical outcome and cost-effectiveness of 1-year nutritional intervention program in COPD. , 2018, , .		0